French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Friday that new data from the HARMONIE Phase 3b clinical trial shows an 83.21% reduction in hospitalizations due to respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD) in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.
The Hospitalized RSV Monoclonal Antibody Prevention (HARMONIE) study collected data from more than 8,000 infants across France, Germany and the UK in a real-world setting during the 2022-2023 RSV season. The data also revealed that nirsevimab reduced the incidence of hospitalizations due to severe RSV-related LRTD by 75.71%.
Additionally, nirsevimab demonstrated a reduction of 58.04% in the incidence of all-cause LRTD hospitalization compared to infants who received no RSV intervention.
The reduction in the overall burden on healthcare systems could be significant if all infants receive nirsevimab, Sanofi said.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib